首次出版:最新修订:March 2009交付方式:特快专递(2-3天送达)
定购电话:0755-82571522、82571566、400-008-1522
24小时服务热线:138 0270 8576 定制报告
版本 | 在线版 | 电子版+印刷版 | 在线报告库(超1000份报告)全库 |
---|---|---|---|
优惠价 | RMB 6800 | RMB 7800 | RMB 9800 |
原价 | RMB 9600 | RMB 9800 | - |
联系电话: 400 008 0586; 0755-82571568
微信扫码:
U.S. Specialty Pharmaceuticals - Overview And Trends
Table of Contents
1 U.S. SPECIALTY PHARMACEUTICALS - OVERVIEW AND TRENDS
· Introduction
o Title
o Disclaimer
o Certification
o Research Scope and Methodology
o Table of Contents
o Introduction
o Current State of Pharma
o Industry Challenges
o Specialty Pharmaceuticals
o Importance of Specialty Pharma
· Business Models
o Business Models
o Business Model Development
o Market Structure
o Business Model Adoption
o Importance of Drug Delivery
o Changing Industry Sales Paradigms
o Specialty Pharma - Operational Focus
· Selected Disease Sectors
o Selected Disease Areas
o Specialty Products - Market Targets
o Pulmonary Arterial Hypertension
o PAH Revenue Forecasts
o Opioid and Non-opioid Pain Management
o Opioid and Non-opioid Pain Management Revenue Forecasts
o Multiple Sclerosis
o MS Revenue Forecasts
o Alzheimer' s Disease
o Alzheimer' s Disease Revenue Forecasts
· Trends in Specialty Pharma
o Trends in Specialty Pharma
o Key Drivers
o Challenges within Specialty Pharma
o Market Trends
· Conclusion
o Conclusion Introduction
o Conclusion
o Opportunities in Specialty Pharma
o Future Competitive Landscape
o Pharmaceutical & Biotechnology Industry Trends
· Appendix
o About Frost & Sullivan
This research service was constructed to provide an overview of trends, business models and selected areas of opportunity in specialty pharmaceuticals. Market forecasts are provided at the total market level for selected disease markets: Pulmonary Arterial Hypertension, Opioid and Non-Opioid Pain Management, Multiple Sclerosis, and Alzheimer' s disease. Challenges and trends for specialty pharma as well as the pharmaceutical and biotechnology industry are discussed as well as future opportunities and market landscape.